Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

Summary

This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

Timeline

Start

2025-11-18

Primary completion

2027-08-01

Completion

2030-11-01

Drugs

Indications